<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">GULER-MARGARITIS, SILVIU</style></author><author><style face="normal" font="default" size="100%">MERCAN-STANCIU, ADRIANA</style></author><author><style face="normal" font="default" size="100%">TOMA, LETITIA</style></author><author><style face="normal" font="default" size="100%">RUSIE, DANIEL</style></author><author><style face="normal" font="default" size="100%">ISAC, TEODORA</style></author><author><style face="normal" font="default" size="100%">DODOT, MIHAI</style></author><author><style face="normal" font="default" size="100%">ZGURA, ANCA</style></author><author><style face="normal" font="default" size="100%">BACALBASA, NICOLAE</style></author><author><style face="normal" font="default" size="100%">HAINEALA, BOGDAN</style></author><author><style face="normal" font="default" size="100%">BADIU, DUMITRU CRISTINEL</style></author><author><style face="normal" font="default" size="100%">SERBAN, DRAGOS</style></author><author><style face="normal" font="default" size="100%">ILIESCU, ELENA LAURA</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">COVID-19 Mid-term Impact on Hepatocellular Carcinoma in Patients With Hepatitis C Chronic Infection</style></title><secondary-title><style face="normal" font="default" size="100%">In Vivo</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">3377-3383</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/invivo.12636</style></doi><volume><style face="normal" font="default" size="100%">35</style></volume><issue><style face="normal" font="default" size="100%">6</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: Liver injury has been frequently reported in association with SARS-CoV-2 infection, but data are still lacking regarding the impact of pre-existing liver damage and neoplasia on SARS-CoV-2 infection outcome and vice-versa. This study aimed to assess the effects of SARS-CoV-2 infection on hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV) infected patients, both in therapeutic-naïve and patients treated with direct acting antivirals. Patients and Methods: We conducted a retrospective cohort study on 21 patients with a personal history of HCV infection, that have been diagnosed with different forms of HCC and who were subsequently infected with SARS-CoV-2. Patients were monitored by liver function tests, tumoral markers, blood cell count, and coagulation profile periodically. Results: Solitary HCC nodules were predominant among the subjects who achieved sustained virologic response, while multinodular and infiltrative patterns were mostly prevalent among the treatment-naïve group. Most patients had mild and moderate COVID-19 infections. Conclusion: Within the current global pandemic crisis, cancer patients are highly vulnerable and in need of constant monitoring. Among patients with HCC, the ones with cured HCV infection may be at a lower risk of fatality than those with active HCV infection, when diagnosed with SARS-CoV-2 infection.</style></abstract></record></records></xml>